SNHG3 regulates NEIL3 via transcription factor E2F1 to mediate malignant proliferation of hepatocellular carcinoma

Zhang, Fabiao; Lu, Jie; Yang, Jian; Dai, Qiqiang; Du, Xuefeng; Xu, Yanping; Zhang, Caiming

doi:10.1007/s00251-022-01277-2

Cited by 11 publications

(7 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SNHG3 is demonstrated to increase the binding of E2F1 and the NEIL3 promoter region to activate NEIL3 transcription, and NEIL3 is shown to participate in SNHG3-mediated HCC cell cycle, apoptosis and proliferation. 23 Collectively, these results were consistent with observation that SNHG3 serves as a risk factor in ccRCC.…”

Section: Discussionsupporting

confidence: 90%

Investigating the prognostic role of lncRNAs associated with disulfidptosis‐related genes in clear cell renal cell carcinoma

Sun,

Wang,

Fan

et al. 2023

The Journal of Gene Medicine

View full text Add to dashboard Cite

IntroductionRenal cell carcinoma (RCC) is a grave malignancy that poses a significant global health burden with over 400,000 new cases annually. Disulfidptosis, a newly discovered programmed cell death process, is linked to the actin cytoskeleton, which plays a vital role in maintaining cell shape and survival. The role of disulfidptosis is poorly depicted in the clear cell histologic variant of RCC (ccRCC).MethodsThree sets of ccRCC cohorts, ICGC_RECA‐EU (n = 91), GSE76207 (n = 32) and TCGA‐KIRC (n = 607), were included in our study, the batch effect of which was removed using the “combat” function. Correlation was calculated using the “rcorr” function of the “Hmisc” package for Pearson analysis, which was visualized using the “pheatmap” package. Principal component analysis was performed by the “vegan” package, visualized using the “scatterplot3d” package. Long non‐coding RNAs (lncRNAs) associated with disulfidptosis were screened out using least absolute shrinkage and selection operator (LASSO) and COX analysis. Tumor mutation, immune landscaping and immunotherapy prediction were performed for further characterization of two risk groups.ResultsA total of 1822 disulfidptosis‐related lncRNAs was selected, among which 308 lncRNAs were found to be significantly associated with the clinical outcome of ccRCC patients. We retained 11 disulfidptosis‐related lncRNAs, namely, AP000439.3, RP11‐417E7.1, RP11‐119D9.1, LINC01510, SNHG3, AC156455.1, RP11‐291B21.2, EMX2OS, AC093850.2, HAGLR and RP11‐389C8.2, through LASSO and COX analysis for prognosis model construction, which displayed satisfactory accuracy (area under the curve, AUC, values all above 0.6 in multiple cohorts) in stratification of ccRCC prognosis. A nomogram model was constructed by integrating clinical factors with risk score, which further enhanced the prediction efficacy (AUC values all above 0.7 in multiple cohorts). We found that patients of male gender, higher clinical stages and advanced pathological T stage were inclined to have higher risk score values. Dactinomycin_1911, Vinblastine_1004, Daporinad_1248 and Vinorelbine_2048 were identified as promising candidate drugs for treating ccRCC patients of higher risk score value. Moreover, patients of higher risk value were prone to be resistant to immunotherapy.ConclusionWe developed a prognosis predicting model based on 11 selected disulfidptosis‐related lncRNAs, the efficacy of which was verified in different cohorts. Furthermore, we delineated an intricate portrait of tumor mutation, immune topography and pharmacosensitivity evaluations within disparate risk stratifications.

show abstract

Section: Discussionsupporting

confidence: 90%

Investigating the prognostic role of lncRNAs associated with disulfidptosis‐related genes in clear cell renal cell carcinoma

Sun,

Wang,

Fan

et al. 2023

The Journal of Gene Medicine

View full text Add to dashboard Cite

show abstract

“…All of this evidence is strengthening the idea that PLGLA can act as a protective factor for LIHC in our study. Currently, several studies have demonstrated than lncRNA SNHG3 plays an oncogenic role in LIHC [ [50] , [51] , [52] ]. Zhang et al explored in depth the molecular regulatory mechanism of lncRNA SNHG3 on the malignant progression of LIHC.…”

Section: Discussionmentioning

confidence: 99%

“…Zhang et al explored in depth the molecular regulatory mechanism of lncRNA SNHG3 on the malignant progression of LIHC. Their study disclosed that reducing SNHG3 expression can reduce tumor size and effectively suppress cancer cell proliferation, and induce apoptosis and G0/G1 phase block [ 51 ]. Moreover, epithelial mesenchymal transition in LIHC cells could be induced via miR-128 / CD151 cascade activation by overexpression of SNHG3 [ 52 ].…”

Section: Discussionmentioning

confidence: 99%

A prognostic exosome-related long non-coding RNAs risk model related to the immune microenvironment and therapeutic responses for patients with liver hepatocellular carcinoma

Yue,

Tao,

et al. 2024

Heliyon

View full text Add to dashboard Cite

“…Angiogenesis played a vital role in the developed HCC. [ 25 ] Hypoxia was also involved in innate immunity and tumor progression in HCC. [ 26 ] Glycolysis shows significant correlation with the prognosis of HCC.…”

Section: Discussionmentioning

confidence: 99%

Identification of vitamin D-related signature for predicting the clinical outcome and immunotherapy response in hepatocellular carcinoma

Wang,

Han,

et al. 2024

Medicine

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common cancers globally, seriously endangering people health. Vitamin D was significantly associated with tumor progression and patients’ prognosis. Integrative 10 machine learning algorithms were used to develop a Vitamin D-related signature (VRS) with one training cohort and 3 testing cohorts. The performance of VRS in predicting the immunology response was verified using several predicting approaches. The optimal VRS was constructed by stepCox + superPC algorithm. VRS acted as a risk factor for HCC patients. HCC patients with high-risk score had a poor clinical outcome and the AUCs of 1-, 3-, and 5-year ROC were 0.786, 0.755, and 0.786, respectively. A higher level of CD8 + cytotoxic T cells and B cells was obtained in HCC patients with low-risk score. There is higher PD1&CTLA4 immunophenoscore and TMB score in low-risk score in HCC patients. Lower TIDE score and tumor escape score was found in HCC cases with low-risk score. The IC50 value of camptothecin, docetaxel, crizotinib, dasatinib, and erlotinib was lower in HCC cases with high-risk score. HCC patients with high-risk score had a higher score of cancer-related hallmarks, including angiogenesis, glycolysis, and NOTCH signaling. Our study proposed a novel VRS for HCC, which served as an indicator for predicting clinical outcome and immunotherapy responses in HCC.

show abstract

SNHG3 regulates NEIL3 via transcription factor E2F1 to mediate malignant proliferation of hepatocellular carcinoma

Cited by 11 publications

References 38 publications

Investigating the prognostic role of lncRNAs associated with disulfidptosis‐related genes in clear cell renal cell carcinoma

Investigating the prognostic role of lncRNAs associated with disulfidptosis‐related genes in clear cell renal cell carcinoma

A prognostic exosome-related long non-coding RNAs risk model related to the immune microenvironment and therapeutic responses for patients with liver hepatocellular carcinoma

Identification of vitamin D-related signature for predicting the clinical outcome and immunotherapy response in hepatocellular carcinoma

Contact Info

Product

Resources

About